<DOC>
	<DOCNO>NCT01623401</DOCNO>
	<brief_summary>This Phase 1 open-label study healthy volunteer receive oral 200 mg TR 701 FA daily 10 day include ophthalmologic neurologic assessment .</brief_summary>
	<brief_title>A Phase 1 , Open-Label , 10 Day Safety Study</brief_title>
	<detailed_description>This Phase 1 open-label study healthy volunteer receive oral 200 mg TR 701 FA daily 10 day ( Days 1 10 ) undergo safety evaluation include ophthalmologic neurologic assessment ( Screening Day -1 ) , 1 day final study drug administration ( Day 11 earlier subject discontinues treatment ) , 2 4 week last study drug administration ( Late Follow-up Visit ) .</detailed_description>
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>Healthy male female ≥ 18 ≤ 65 year age clinically significant abnormality identify detailed medical history Female subject must nonpregnant , nonlactating , either postmenopausal least 2 year , surgically sterile least 90 day , abstinent , agree use contraception 1 week prior Day 1 30 day leave study center . Male subject must surgically sterile , abstinent , agree use contraception Day 1 30 day leave study center BMI ≥ 18.0 kg/m2 ≤ 35.0 kg/m2 Hypersensitivity oxazolidinones component formulation History current significant ophthalmologic neurologic condition would adversely affect clinical assessment confound interpretation data ( e.g. , dense cataract , macular degeneration , retinitis pigmentosa ) Positive hepatitis B surface antigen , hepatitis C virus antibody , human immunodeficiency virus antibody test result Known genetic condition relate mitochondrial disease dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>